In these cases, we hypothesize that the use of a neoantigen vaccine11 to increase the frequency of tumor-specific T cells could be particularly effective in combination with CD25-biased IL-2cx/IC to efficiently stimulate antitumor immunity. Here, IL2RA is linked to neoplasm.